Sara Nik
Stock Analyst at H.C. Wainwright
(3.11)
# 2,492
Out of 4,349 analysts
36
Total ratings
22.2%
Success rate
7.6%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Sara Nik
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| STO: CANTA Cantargia AB (publ) | Reiterated: Buy | kr 14.00 | $2.92 | +379.45% | 7 | May 22, 2026 | |
| KTTA Pasithea Therapeutics | Reiterated: Buy | $3 | $0.6971 | +330.35% | 6 | May 21, 2026 | |
| MBRX Moleculin Biotech | Reiterated: Buy | $22 | $2.74 | +702.92% | 15 | May 15, 2026 | |
| CRIS Curis | Reiterated: Buy | $17 | $0.5234 | +3,147.99% | 7 | May 13, 2026 | |
| KAPA Kairos Pharma | Reiterated: Buy | $12 | $0.527 | +2,177.04% | 1 | Aug 13, 2025 |
Cantargia AB (publ)
May 22, 2026
Reiterated: Buy
Price Target: kr 14.00
Current: $2.92
Upside: +379.45%
Pasithea Therapeutics
May 21, 2026
Reiterated: Buy
Price Target: $3
Current: $0.6971
Upside: +330.35%
Moleculin Biotech
May 15, 2026
Reiterated: Buy
Price Target: $22
Current: $2.74
Upside: +702.92%
Curis
May 13, 2026
Reiterated: Buy
Price Target: $17
Current: $0.5234
Upside: +3,147.99%
Kairos Pharma
Aug 13, 2025
Reiterated: Buy
Price Target: $12
Current: $0.527
Upside: +2,177.04%